P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017

Publisher Name :
Date: 18-Jul-2017
No. of pages: 52

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017

Summary

P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein that in humans is encoded by the P2RX3 gene. It belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel and may transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3 and 3 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Respiratory, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Neuropathic Pain, Chronic Cough, Chronic Pain, Hypertension, Visceral Pain, Abdominal Pain, Alzheimer's Disease, Endometriosis, Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Insomnia, Interstitial Cystitis (Painful Bladder Syndrome), Memory Impairment, Migraine, Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis Pain, Pain, Resistant Hypertension and Respiratory Tract Infections.

The latest report P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017, outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)

- The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects

- The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 3 (P2RX3) - Overview
P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
Asana BioSciences LLC
Bayer AG
BELLUS Health Inc
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Pfizer Inc
P2X Purinoceptor 3 (P2RX3) - Drug Profiles
AF-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize P2X3 for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 Backups - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 3 (P2RX3) - Dormant Products
P2X Purinoceptor 3 (P2RX3) - Discontinued Products
P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
Featured News & Press Releases
May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease
Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease
Sep 05, 2016: Hypertension: releasing the pressure at its source
May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference
May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference
Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial
Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients
Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Asana BioSciences LLC, H2 2017
Pipeline by Bayer AG, H2 2017
Pipeline by BELLUS Health Inc, H2 2017
Pipeline by Integral Molecular Inc, H2 2017
Pipeline by Merck & Co Inc, H2 2017
Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
Pipeline by Pfizer Inc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global and United States Biobanking In-Depth Research Report 2017-2022
    Published: 20-Oct-2017        Price: US 3190 Onwards        Pages: 120
    The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022. This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Biobanking industry. Major Companies - Thermo Fisher Scientific Inc. (U.S.) - Tecan Group Ltd. ......
  • Global Biobanking Market Research Report 2017-2022 by Players, Regions, Product Types & Applications
    Published: 19-Oct-2017        Price: US 2380 Onwards        Pages: 124
    The global Biobanking market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. This report offers an overview of the market trends, drivers, and barriers with respect to the Biobanking market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Biobanking market by By P......
  • Global and Europe Biobanking Market - Analysis and Outlook to 2022
    Published: 19-Oct-2017        Price: US 2960 Onwards        Pages: 130
    This report presents a comprehensive overview of the Biobanking market in Europe, which shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. This report provides a detailed analysis of the market, including its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Biobanking industry. This report focuses Global and Europ......
  • 2017-2022 Global and Japan Biobanking Market Analysis Report
    Published: 19-Oct-2017        Price: US 3085 Onwards        Pages: 120
    The global Biobanking market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022. Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%. This report, with focus on top players in the global and Japan, studies the Biobanking market's development status and future trend in the global and ......
  • Global Biobanking Detailed Analysis Report 2017-2022
    Published: 19-Oct-2017        Price: US 3250 Onwards        Pages: 121
    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Biobanking industry. This report splits Biobanking market By Product and Service, By Sample, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022. This report focuses Global market, it covers detai......
  • Global and Regional Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market Research Report 2017
    Published: 19-Oct-2017        Price: US 3500 Onwards        Pages: 105
    Summary Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival.EGF considerably increases skin cell regeneration. More precisely, they can directly communicate to the skin cells to produce more collagen and elastin, that's wh......
  • China Contract Research Organization (CRO) Industry Report, 2017-2021
    Published: 18-Oct-2017        Price: US 2700 Onwards        Pages: 110
    Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the development of new drugs assisted by CRO firms in recent years, stimulating the progression of global CRO industry which had a market size of USD31.7 billion in 2016. There are more than 1,100 CRO companies around the world, led by Quintiles IMS, Covance, in Ventiv Health, Charles River, Parex......
  • Global Digital PCR (dPCR) Sales Market Report 2017
    Published: 18-Oct-2017        Price: US 4000 Onwards        Pages: 111
    In this report, the global Digital PCR (dPCR) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Digital PCR (dPCR) for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japa......
  • Global Somatostatin Sales Market Report 2017
    Published: 18-Oct-2017        Price: US 4000 Onwards        Pages: 114
    In this report, the global Somatostatin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Somatostatin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Sout......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs